Cas No.Product NameDescription
852808-04-9ABT-737ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts.
19171-19-8PomalidomidePomalidomide is tumor necrosis factor-α inhibitor and a new immunomodulator with an IC50 of 1 μM.
923564-51-6NavitoclaxNavitoclax is a novel, oral BH3 mimetic, potently inhibits multiple antiapoptotic Bcl-2 family proteins.
781661-94-7YM155YM155 (YM155; Sepantronium bromide) is a novel small molecule survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
881202-45-5SerdemetanSerdemetan is an orally bioavailable, first-in-class small-molecule HDM2 antagonist with potential antineoplastic activity.
315183-21-2PAC-1PAC 1 is a procaspase-activating compound, which in turn produces caspase-3 (EC50 = 0.22 μM). PAC 1 also activates procaspase-7 in a less efficient manner (EC50 = 4.5 μM). This compound is a proapoptotic, inducing apoptosis in both cancerous and non-cancerous cell lines.
273404-37-8VX-765VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively.
90141-22-3AT101AT-101 is orally bioavailable solvate of R-(-)-enantiomer of gossypol with potential antineoplastic activity.
675576-98-4Nutlin-3aNutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM.
675576-97-3Nutlin-3bNutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.
1233533-04-4 kb NB 142-70kb NB 142-70 is a selective protein kinase D (PKD) inhibitor (IC50 values are 28.3, 58.7 and 53.2 nM for PKD1, 2 and 3 respectively).
213261-59-7 RITA NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. RITA,a drug that, like nutlin-3, can disrupt the p53/Mdm2 interaction.
79183-19-0 Apoptosis Activator 2Apoptosis Activator 2 strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells.
187389-52-2Z-VAD-FMKZ-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis.
6964-62-1NSC 66811Potent MDM2 inhibitor (Ki = 120 nM) which disrupts MDM2-p53 interaction and activates p53 function. Induces p21, p53 and MDM2 accumulation in human colon cancer cells in vitro.
1257628-77-5GZD824GZD824 is a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I. GZD824 tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K(d) values of 0.32 and 0.71 nM, respectively,
1005342-46-0LCL161LCL161 is an oral small molecule antagonist of Inhibitor of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies.
1260251-31-7Birinapant Birinapant, also known as TL32711, is a synthetic small molecule and peptido mimetic of second mitochondrial-derived activator of caspases and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity.
873652-48-3GDC-0152GDC-0152 is a potent inhibitor of IAPs; binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively.
1001600-56-1BV6BV6 is a small-molecule Smac mimetic, which antagonizes IAP and induces autoubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway